fashion -WSS

fashion

author：fashion 2025-09-29 21:23:05 - browse：9614

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Russian court extends detention of American musician

leisure time

focus

WSS

Will an HIV vaccine ever be a reality?

Some top drug companies are starting to take action on climate

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

Health insurers' Q3 question: how much care are people getting?

Medical mystery: When an infection after surgery isn’t what it seems

Slain Parkland victim's father speaks out following reenactment

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

What does generative AI mean for health care? We asked experts

Flu, Covid vaccination rates decline, new survey data show

Virginia high school admissions case could be legal follow

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Sports medicine is finally prioritizing gender equality

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

After affirmative action ruling, medical educators look to 'holistic review'

The biotech scorecard for Q4: 16 stock

Wikipedia

The United States is paying nearly triple for new Covid vaccines

Rock icon Freddie Mercury pre

RSV injection headlines need to be accurate for good uptake

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

The Karikó problem: Lessons for funding basic research

leisure time

focus

focus

https://cbu01.alicdn.com/img/ibank/2017/575/578/4316875575_378017202.220x220xz.jpg